Docebo stock went into this earnings print already on a strong run, up about 19% over the past three months and closing at CA$31.09 on the day of the release. The headline this quarter is clear. Revenue reached US$68.65m and basic earnings per share came in at US$0.09, which marks a clean swing back into profit after a loss in Q1.
In the very short term traders will focus on that earnings rebound. Long term investors will weigh it against a P/E of 16.5x and a discounted cash flow estimate that sits far above the current share price.
Is Docebo trading at a rare disconnect to its fundamentals, or are investors correctly discounting the balance sheet risks and one-off loss? See how the DCF, P/E and peer comparisons line up in our valuation analysis for Docebo
Prefer clean charts instead of another wall of earnings tables and footnotes? See Docebo's full financial picture with an at-a-glance view of its valuation in our company report for Docebo.
Bulls argue Docebo’s AI led product push and enterprise focus should translate into faster growth, richer contracts and stronger margins. Q2 gives some support. Revenue reached US$68.65m and trailing net margin for the last twelve months improved to 13.0% from 9.3%. That lines up with the idea that operating discipline and higher value deals are starting to show up in profitability, even though quarterly net income of US$2.26m and EPS of US$0.09 sit slightly below Q2 2025. Management raised full year revenue guidance by US$3.5m and ties the uplift to enterprise pipeline, FedRAMP enabled public sector opportunities and AI rich modules such as AgentHub and Enterprise Knowledge. ARR re acceleration across net new, expansion and international, plus higher win rates tied to 365Talents, are concrete execution signals for the bullish narrative.
The bear view centers on slower growth, lumpier enterprise deals, balance sheet risk and uncertain AI monetization. Q2 does not dismiss those concerns. Revenue is higher year on year but net income and EPS are lower than Q2 2025, so earnings leverage is not yet consistent. Management kept EBITDA guidance unchanged even after lifting revenue guidance and explicitly pointed to rising R&D spend on healthcare, AgentHub and the forward deployed engineer model. That supports worries that new AI and vertical plays may be expensive before they scale. Roughly US$45m cash against about US$90m of debt, along with a potential share buyback that could increase debt in the short term, keeps balance sheet caution in play. Heavy reliance on partners for about 80% of large enterprise pipeline and early stage integrations for 365Talents and Zive mean execution risk remains central to the bearish case.
After rising R&D, one-off items and leveraged debt, are these visible pressures masking deeper structural threats? Review our risk analysis for Docebo which shows 3 important warning signsIf Docebo's rebound in profitability and the gap between its P/E and discounted cash flow estimate have caught your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for your preferred entry point. Once you are invested, keep a clear view of your positions and cut through market noise with the Portfolio Command Center that highlights only the most important developments. For a broader perspective on Docebo and other stocks, lean on the collective insights of thousands of investors through the Community. By spotting hidden catalysts and risks early, you give yourself a better chance to stay ahead of the market.
Fresh ideas move first. The stocks that quietly build momentum often break out while most investors are caught looking back. Scan these curated shortlists while it matters and aim to get in earlier in the cycle.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com